Top Suppliers:I want be here


  • DC Chemicals Limited
  • China
  • Product Name: YK-3-237
  • Price: $Inquiry/25mg $Inquiry/100mg $Inquiry/500mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

1215281-19-8

1215281-19-8 structure
1215281-19-8 structure
  • Name: YK 3-237
  • Chemical Name: {2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl}boronic acid
  • CAS Number: 1215281-19-8
  • Molecular Formula: C19H21BO7
  • Molecular Weight: 372.177
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage Sirtuin
  • Create Date: 2018-07-05 01:24:58
  • Modify Date: 2024-01-11 20:26:41
  • YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells[1].

Name {2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl}boronic acid
Synonyms MFCD28167612
Boronic acid, B-[2-methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]-
{2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl}boronic acid
Description YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells[1].
Related Catalog
Target

SIRT1

In Vitro YK-3-237 exhibits the anti-proliferative activities toward most of the breast cancer cell lines tested at submicromolar concentration. YK-3-237 preferentially inhibits the proliferation of breast cancer cell lines carrying mtp53[1]. YK-3-237 inhibits the proliferation of triple-negative breast cancer (TNBC) HS578T, MDA-MB-453, SUM1315MO2, SUM149PT, BT549, MDA-MB-231, MDA-MB-436, MDA-MB-468, HCC1937 with IC50s of 0.160±0.043, 0.241±0.086, 0.253±0.028, 0.289±0.066, 0.353±0.017, 0.431±0.136, 0.501±0.062, 1.436±0.754, 5.031±2.010 µM, respectively[1]. YK-3-237 inhibits the proliferation of Luminal T47D, MCF7, and ZR-75-1 with IC50s of 1.573±0.370, 2.402±0.256, 3.822±0.967 µM, respectively[1]. YK-3-237 inhibits the proliferation of HER2 BT474 and SK-BR-3 with IC50s of 1.249±0.372 and 0.346±0.066 µM, respectively[1]. YK-3-237 (0.01-10 µM; 24 hours) deacetylates mtp53 in TNBC cell lines[1]. YK-3-237 is a potent activator of Sirt1, on the activation of renal interstitial fibroblasts using NRK-49F cells[2]. Exposure of cells to YK-3-237 also significantly reduces expression of α-SMA and fibronectin in a dose-dependent manner, with the maximum inhibition occurring at 10 μM[2]. Cell Viability Assay[1] Cell Line: BT549, MDA-MB-468, HS578T, SUM149PT Concentration: 0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 µM Incubation Time: 24 hours Result: Reduced both the acetylation of K382 and the level of mtp53 in a dose-dependent manner in mtp53 TNBC cell lines.
References

[1]. Yong Weon Yi, et al. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget. 2013 Jul;4(7):984-94.

[2]. Murugavel Ponnusamy, et al. Activation of Sirtuin-1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis. J Pharmacol Exp Ther. 2015 Aug;354(2):142-51.

Density 1.3±0.1 g/cm3
Boiling Point 616.2±65.0 °C at 760 mmHg
Molecular Formula C19H21BO7
Molecular Weight 372.177
Flash Point 326.5±34.3 °C
Exact Mass 372.138031
LogP 3.52
Vapour Pressure 0.0±1.9 mmHg at 25°C
Index of Refraction 1.577